Enoxaparin vs fondaparinux

Mesoridazine
Cerivastatin
Frova
Methotrexate

SYNTAX INTEGER MAX-ACCESS read-only STATUS current DESCRIPTION " The type of Reachable address. Those of type manual are created by the network manager. Those of type automatic are created through propogation of routing information from another routing protocol eg. IDRP ; . " DEFVAL : : -- The IP Reachable Address Group -- The IP Reachable Address Group is optional. -- The IP Reachable Address Table -- Each entry records information about one IP reachable -- address manually configured on this system or learned from -- another protocol. isisIPRATable OBJECT-TYPE SYNTAX SEQUENCE OF IsisIPRAEntry MAX-ACCESS not-accessible STATUS current DESCRIPTION "The table of IP Reachable Addresses to networks, subnetworks or hosts either manually configured or learned from another protocol." : : isisIPRAEntry OBJECT-TYPE SYNTAX IsisIPRAEntry MAX-ACCESS not-accessible STATUS current DESCRIPTION "Each entry defines an IP Reachable Address to a network, subnetwork or host." INDEX isisIPRASysInstance, Expires October 1999 [Page 65]. For E84C is slightly slower than that for wild type enzyme. By contrast, E81C shows no difference in the kinetic constants. Conjugation of acrylodan, a neutral naphthalene derivative, with E84C reduces kon of TFK 7-fold compared with unconjugated E84C, whereas conjugation of E81C with acrylodan only reduces kon of TFK slightly. For acrylodan-labeled mutants, kon was measured from the time-dependent decrease of fluorescence signal Fig. 3 ; . Influence of Residue Modification on Inhibition by Noncovalent Active Site Inhibitors--A similar trend in inhibition kinetics was seen with noncovalent active site inhibitors such as edrophonium and BW286c51 Table II ; . An increase over wild type Kd of 2-fold occurs for edrophonium binding to E84C, and. The plasma heparin dependent factor of twenty-five patients with heparin associated thrombocytopenia. Thromb Haemost. 1995; 74: 1384 Walenga JM, Koza MJ, Lewis BE, Pifarre R. Relative heparin-induced thrombocytopenic potential of low molecular weight heparins and new antithrombotic agents. Clin Appl Thromb Hemost. 1996; 2 suppl 1 ; : S21. Amiral J, Lormeau JC, Marfaing-Koka A, Vissac AM, Boyer-Neumann C, Tardy B, Herbert M, Meyer D. Absence of cross-reactivity of SR 90107A ORG 31540 pentasaccharide with antibodies to heparin-PF4 complexes developed on heparin-induced thrombocytopenia. Blood Coagul Fibrinolysis. 1997; 8: 114 Walenga J, Jeske W, Bara L, Samama MM, Fareed J. Biochemical and pharmacological rationale for the development of a synthetic heparin pentasaccharide. Thromb Res. 1997; 86: 136. Boneu B, Necciari J, Cariou R, Sie P, Gabaig AM, Kieffer G, Dickinson J, Lamond G, Moelker H, Mant T. Pharmacokinetics and tolerance of the natural pentasaccharide SR90107A ORG31540 ; with high affinity to antithrombin III in man. Thromb Haemost. 1995; 74: 1468 Herbert JM, Herault JP, Bernat A, van Amsterdam RG, Lormeau JC, Petitou M, vanBoeckel C, Hoffmann P, Meuleman DG. Biochemical and pharmacological properties of SANORG 34006, a potent and longacting synthetic pentasaccharide. Blood. 1998; 91: 4197 Bijsterveld NR, Moons AH, Boekholdt SM, van Aken BE, Fennema H, Peters RJ, Meijers JC, Buller HR, Levi M. Ability of recombinant factor VIIa to reverse the anticoagulant effect of the pentasaccharide fondaparinux in healthy volunteers. Circulation. 2002; 106: 2550 Eriksson BI, Bauer KA, Lassen MR, Turpie AGG, for the Steering Committee of the Pentasaccharide in Hip Fracture Surgery Study. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. N Engl J Med. 2001; 345: 1340 Turpie AGG, Bauer K, Eriksson BI, Lassen MR, for the Pentathlon 2000 Study Steering Committee. Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trial. Lancet. 2002; 359: 17211726. Lassen MR, Bauer KA, Eriksson BI, Turpie AGG, for the European Pentasaccharide Hip Elective Surgery Study EPHESUS ; Steering Committee. Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement in elective hip-replacement surgery: a randomised double-blind comparison. Lancet. 2002; 359: 17151720. Turpie AGG, Bauer KA, Eriksson BI, Lassen MR, for the Steering Committees of the Pentasaccharide Orthopedic Prophylaxis Studies. Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies. Arch Intern Med. 2002; 162: 18331840. Bauer KA, Eriksson MD, Lassen MR, Turpie AGG, for the Steering Committee of the Pentasaccharide in Major Knee Surgery Study. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after major elective knee surgery. N Engl J Med. 2001; 345: 13051310. Bauer KKA, Eriksson BI, Lassen MR, Turpie AGG. Influence of the duration of fondaparinux prophylaxis in preventing venous thromboembolism following hip fracture surgery. Blood. 2002; 100: 83a. Abstract. Matisse Investigators. Fondaparinux Arixtra ; in comparison to lowmolecular weight heparin for the initial treatment of symptomatic deep venous thrombosis or pulmonary embolism: the Matisse clinical outcome studies. Blood. 2002; 100: 83a. Abstract. Coussement PK, Bassand JP, Convens C, Vrolix M, Boland J, Grollier G, Michels R, Vahanian A, Vanderheyden M, Rupprecht HJ, Van de Werf F. A synthetic factor Xa inhibitor ORG31540 SR9017A ; as an adjunct to fibrinolysis in acute myocardial infarction. Eur Heart J. 2001; 22: 1716 Fergusson JJ. Meeting highlights: American Heart Association scientific sessions 2001. Circulation. 2002; 105: e37 e41. Persist Investigators. A novel long-acting synthetic factor Xa inhibitor idraparinux sodium ; to replace warfarin for secondary prevention in deep vein thrombosis: a phase II evaluation. Blood. 2002; 100: 82a. Abstract. Vlasuk GP. Structural and functional characterization of tick anticoagulant peptide TAP ; : a potent and selective inhibitor of blood coagulation factor Xa. Thromb Haemost. 1993; 70: 212216. Tuszyuski G, Gasic TB, Gasic GJ. Isolation and characterization of antistasin. J Biol Chem. 1987; 262: 9718.

Enoxaparin units

Aram V. Chobanian, George L. Bakris, Henry R. Black, William C. Cushman, Lee A. Green, Joseph L. Izzo, Jr, Daniel W. Jones, Barry J. Materson, Suzanne Oparil, Jackson T. Wright, Jr, Edward J. Roccella, and the National High Blood Pressure Education Program Coordinating Committee. Safety of combined hypolipidemic treatment . 41 Current problems of utilization of analgesic drugs . 41 Bezpecnos kombinovanej hypolipidemickej liecby 41 Aktulne problmy utilizcie analgetk . 41.
Surgical intervention for obesity : bmi 40 kg m2 heparin: keep ptt 5- 0 x control warfarin: keep pt 5- 8 x control enoxaparin lmwh ; : no ptt monitoring required copd : smooth muscle hyperplasia as in asthma ; , but methacholine challenge test is negative reid index: ratio of thickness of bronchial glands to bronchial wall thickness increased in chronic bronchitis ; nicotine enhances growth of flu most effective long term pharmacotherapy for copd: ipratropim bromide copd excecacerbations: flu, pneumococcus, moraxella long term home oxygen therapy only rx in copd that enhances survival indications: resting pao2 resting pao2 cor pulmonale polycythemia ; aster's usmle step3 notes page 26 of 94 may 19, 2003 acute bronchitis in healthy non-smoker: no investigations, no treatment no antibiotics ; early phase of asthma: primary mediators late phase of asthma: secondary mediators prophylaxis of exercize induced asthma: albuterol long term stabilization of exercize induced asthma: salmetrol long acting ; + zafirlukast mycoplasma pneumonia: minimum physical findings b l lower lobe infiltrates cough + ; mx: macrolide cold agglutinins igm ; inravascular hemolysis pnenumonia in elderly debilitated alcoholic: lower lobe: strep pneumoniae upper lobe: klebsiella currant jelly sputum, hemoptysis, cavitatory lesion ; normal semen analysis vol and entacapone. Fondaparinux Group Elective Hip Replacement Type of surgery Primary Revision Use of cement Mean SD duration of surgery, h: min 1950 2257 86.4 ; 307 2257 13.6 ; 1251 2255 55.5 ; 2: 25 0: 1956 2253 ; 297 2253 13.2 ; 1271 2249 56.5 ; 2: 26 0: Enoxaparin Group. Aneurysm Detection Management ADAM ; Veterans Affairs Cooperative Study Investigators 1997 ; . Relationship of age, gender, race, and body size to infrarenal aortic diameter. Journal of Vascular Surgery, 26 4 ; : 595-601. Aneurysm Detection and Management ADAM ; Veterans Affairs Cooperative Study Group 1997 ; . Prevalence and associations of abdominal aortic aneurysm detected through screening. Annals of Internal Medicine, 126 6 ; : 441-9. Abdominal Aortic Aneurysm Detection and Management Veterans Administration Cooperative Study Group 1995 ; . Variability in measurement of abdominal aortic aneurysms. Journal of Vascular Surgery, 21 6 ; : 945-52. Davis WJ, Smith SV 1995 ; . Properties of human affect induced by static color slides IAPS ; : Dimensional, categorical and electromyographic analysis. UC Santa Cruz, Biological Psychology, 41 3 ; : 229-53. Smith SV 1993 ; . Synergistic combined therapies in the treatment of HIV. UC Santa Cruz, Disclosure Document, US Patent Office. Smith SV 1978 ; . The Dimensions of Personhood. WACPS Conference, Journal of Psychology and Theology. Smith SV 1978 ; . Points of Integration Between Carl Rogers and Karl Barth. WACPS Conference, Journal of Psychology and Theology and entecavir.

Enoxaparin action

Allergic rhinitis are antihistamines and intranasal corticosteroids. Many of these medications are!

The difficulty in life is the choice." George Moore he sheer scope of the burden of acute ischemic heart disease, initially evident in Western civilization but now increasingly a global problem, places a high priority on understanding its pathophysiology and identifying individuals at increased risk of morbid and mortal events. So too is there strong impetus for the timely development and introduction of cost-effective therapeutic solutions coupled with concurrent strategies for both primary and secondary prevention. tissue proteins and are more bioavailable, they are capable of producing both a longer and more predictable anticoagulant effect without the need for laboratory monitoring. Other advantages of LMWH include enhanced anti-Xa activity, relative resistance to the neutralizing effect of platelet factor IV it is also able to inhibit factor Xa located on platelet surfaces ; , inhibition of Von Willebrand factor, and facilitation of tissue factor inhibitor release. LMWH achieve their lighter status approximately 4500 to 6000 d ; through enzymatic or chemical depolymerization. The exact mechanisms for their efficacy and hemorrhagic effects are unknown but variation in the ratio of anti-Xa to anti-IIa between 2 to 4: have led to speculation that measuring the anti-Xa activity might provide the potential for meaningful biological monitoring. Initial studies in patients with venous thromboembolism confirmed stable therapeutic efficacy, avoidance of the need for laboratory monitoring, and acceptance of patient selfadministration, thereby improving cost efficacy through reduced length of hospital stay.6 Given the widespread use of heparin, the lower incidence of LMWH-induced thrombocytopenia presumed secondary to its reduced binding to platelets and platelet factor IV ; is a welcome additional advantage. Because of the initial success with LMWH in venous thromboembolism, application of this therapy to acute coronary syndromes was a logical next step. Unequivocal evidence concerning the dalteparin variety of LMWH as compared to placebo emerged from the FRISC trial, which demonstrated a 3% absolute and 63% relative risk reduction in death or new MI at 6 days. Attenuation of the benefit of q12h dalteparin 120 IU kg given for 6 days with a once-daily fixed dose regimen of 7500 IU over 35 to 45 days ; raised the possibility that a more effective, prolonged treatment regimen might better sustain or even enhance early benefit.7 The FRIC investigators, using a similar dalteparin regimen, found no improvement and possibly less favorable effects compared to unfractionated heparin during the hospital course: no advantage over aspirin was evident after sustained dalteparin therapy for 45 days.8 Two years ago, the ESSENCE investigators first reported on the therapeutic effects of enoxaparin compared with unfractionated heparin in patients with unstable coronary disease.9 The risk of a composite primary end point of death, myocardial infarction, or recurrent angina at 14 days was reduced from 19.8% to 16.6% odds ratio 0.80; 95% CI 0.67 0.96 ; . Although no benefit was evident at 48 hours, there was persistence of the 14-day benefit, largely driven by recurrent angina, through 30 days. This has recently been found durable at 1-year follow-up.10 An additional mechanism for benefit in these patients may well be the observation of reduced rebound ischemia, previously demonstrated after cessation of unfractionated heparin.10, 11 and entex.

Buy generic Enoxaparin online

Also significantly increased the AMI risk. For current use of valdecoxib, the RR was 4.60 95% CI, 0.61 to 34.51 ; . RRs appeared to increase with higher daily doses of COX-2 inhibitors and were also increased in patients without major cardiovascular risk factors. Antman EM, et al. Enoxaparin versus Unfractionated Heparin with Fibrinolysis for ST-Elevation Myocardial Infarction. EXTRACT-TIMI 25 ; N Engl J Med. 2006 Mar 20; [Epub ahead of print] Conclusions In patients receiving fibrinolysis for ST-elevation myocardial infarction, treatment with enoxaparin throughout the index hospitalization is superior to treatment with unfractionated heparin for 48 hours but is associated with an increase in major bleeding episodes. InfoPOEMs: For every 1000 patients treated with enoxaparin instead of unfractionated heparin there were 15 fewer nonfatal myocardial infarctions MIs ; , 7 fewer urgent revascularizations, and 6 fewer deaths, but there were 4 additional episodes of nonfatal major bleeding. LOE 1b Andraws R, Berger JS, Brown DL. Effects of antibiotic therapy on outcomes of patients with coronary artery disease. A meta-analysis of randomized controlled trials. JAMA 2005; 293: 2641-47. InfoPOEMs: Antibiotic therapy is no more effective than placebo in reducing the morbidity or mortality in patients with acute coronary syndromes. LOE 1a- Armstrong PW. A comparison of pharmacologic therapy with without timely coronary intervention vs. primary percutaneous intervention early after ST-elevation myocardial infarction: the WEST Which Early ST-elevation myocardial infarction Therapy ; study. Eur Heart J. 2006 Jun 6; [Epub ahead of print] Assessment of the Safety and Efficacy of a New Treatment Strategy with Percutaneous Coronary Intervention ASSENT-4 PCI ; investigators. Primary versus tenecteplase-facilitated percutaneous coronary intervention in patients with ST-segment elevation acute myocardial infarction ASSENT-4 PCI ; : randomised trial. Lancet. 2006 Feb 18; 367 9510 ; : 569-78. Assmus B, et al. Transcoronary transplantation of progenitor cells after myocardial infarction. N Engl J Med. 2006 Sep 21; 355 12 ; : 1222-32. Bhatt DL, Fox KA, Hacke W, et al. Clopidogrel and Aspirin versus Aspirin Alone for the Prevention of Atherothrombotic Events. N Engl J Med. 2006 Mar 12; Charisma ; [Epub ahead of print] InfoPOEMs: The use of the combination of clopidogrel Plavix ; and aspirin should be limited to carefully defined groups of patients with acute coronary syndromes. It is not recommended for the broader group of patients with coronary disease, cerebrovascular disease, or multiple risk factors such as diabetes, hyperlipidemia, & hypertension. LOE 1b Boersma E; The Primary Coronary Angioplasty vs. Thrombolysis Group. Does time matter? A pooled analysis of randomized clinical trials comparing primary percutaneous coronary intervention and in-hospital fibrinolysis in acute myocardial infarction patients. Eur Heart J. 2006 Apr; 27 7 ; : 779-88. Epub 2006 Mar 2. Bradley EH, et al. Strategies for Reducing the Door-to-Balloon Time in Acute Myocardial Infarction. N Engl J Med. 2006 Nov 13; [Epub ahead of print] Bradshaw PJ, et al. Validity of the GRACE Global Registry of Acute Coronary Events ; acute coronary syndrome prediction model for six month post-discharge death in an independent data set. Heart. 2006 Jul; 92 7 ; : 905-9. Epub 2005 Dec 30. Brugts JJ, Knetsch AM, Mattace-Raso FU, Hofman A, Witteman JC. Renal function and risk of myocardial infarction in an elderly population: the Rotterdam Study. Arch Intern Med. 2005 Dec 12-26; 165 22 ; : 2659-65. Cheung NW, Wong VW, McLean M. The hyperglycemia: intensive insulin infusion in infarction HI-5 ; study: a randomized controlled trial of insulin infusion therapy for myocardial infarction. Diabetes Care. 2006 Apr; 29 4 ; : 765-70. Cleland JG, et al.; Cardiac Resynchronization-Heart Failure CARE-HF ; Study. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med. 2005 Apr 14; 352 15 ; : 1539-49. Epub 2005 Mar 7. Cheung NW, et al. The Hyperglycemia: Intensive Insulin Infusion in Infarction HI-5 ; study: a randomized controlled trial of insulin infusion therapy for myocardial infarction. Diabetes Care. 2006 Apr; 29 4 ; : 765-70. Choudhry NK, Singh JM, Barolet A, Tomlinson GA, Detsky AS. How should patients with unstable angina and non-ST-segment elevation myocardial infarction be managed? A meta-analysis of randomized trials. J Med. 2005 May; 118 5 ; : 465-74 & ACP Journal Club . Collet JP, Montalescot et al. Percutaneous coronary intervention after fibrinolysis: a multiple meta-analyses approach according to the type of strategy. J Coll Cardiol. 2006 Oct 3; 48 7 ; : 1326-35. Epub 2006 Sep 14. Comparison of Fondaparinux and Enoxaparin in Acute Coronary Syndromes. OASIS-5 ; N Engl J Med. 2006 Mar 14; [Epub ahead of print] Conclusions Fondaparinux is similar to enoxaparin in reducing the risk of ischemic events at nine days, but it substantially reduces major bleeding and improves long term mortality and morbidity. Cooper WO, et al Major congenital malformations after first-trimester exposure to ACE inhibitors. N Engl J Med. 2006 Jun 8; 354 23 ; : 2443-51. Digoxin Ahmed A, et al. Digoxin and reduction in mortality and hospitalization in heart failure: a comprehensive post hoc analysis of the DIG trial. Eur Heart J. 2006 Jan; 27 2 ; : 178-86. Epub 2005 Dec 8. & Adams KF Jr, et al. Relationship of serum digoxin concentration to mortality and morbidity in women in the digitalis investigation group trial: a retrospective analysis. J Coll Cardiol. 2005 Aug 2; 46 3 ; : 497-504. de Winter RJ, Windhausen F, Cornel JH, et al. Invasive vs Conservative Treatment in Unstable Coronary Syndromes ICTUS ; Investigators. Early invasive vs selectively invasive management for acute coronary syndromes. N Engl J Med. 2005 Sep 15; 353 11 ; : 1095-104.

Enoxaparin for women

Renal adjustment for patients with CrCl 30 mL min: Enoxaparin 30 mg subcutaneously once daily. Duration days and epirubicin.

Enoxaparin heparin

Use Tier 1 choice i.e. generic Celexa ; for a lower copayment LEXAPRO ST ; PAXIL CR ST ; EFFEXOR XR ST ; WELLBUTRIN XL. CLEXANE CLEXANE 20 mg contains 20 mg enoxaparin sodium in 0.2 mL water for injection, as a clear, colourless to pale yellow solution in a single dose ready-to-use pre-filled syringe. CLEXANE 40 mg contains 40 mg enoxaparin sodium in 0.4 mL water for injection, as a clear, colourless to pale yellow solution in a single dose ready-to-use pre-filled syringe. CLEXANE 60 mg contains 60 mg enoxaparin sodium in 0.6 mL water for injection, as a clear, colourless to pale yellow solution in a single dose ready-to-use pre-filled graduated syringe. CLEXANE 80 mg contains 80 mg enoxaparin sodium in 0.8 mL water for injection, as a clear, colourless to pale yellow solution in a single dose ready-to-use pre-filled graduated syringe. CLEXANE 100 mg contains 100 mg enoxaparin sodium in 1 mL water for injection, as a clear, colourless to pale yellow solution in a single dose ready-to-use pre-filled graduated syringe. CLEXANE FORTE SYRINGES CLEXANE FORTE 120 mg contains 120 mg enoxaparin sodium in 0.8 mL water for injection, as a clear, colourless to pale yellow solution in a single dose ready-to-use pre-filled graduated syringe. CLEXANE FORTE 150 mg contains 150 mg enoxaparin sodium in 1.0 mL water for injection, as a clear, colourless to pale yellow solution in a single dose ready-to-use pre-filled graduated syringe and eplerenone You and your doctor need to know how well your treatment plan is working, or if changes need to be made. It is important to know what your blood sugar levels are when you visit the doctor for your diabetes care. You also need to know if your blood sugar levels are within normal range between visits and if your diabetes meal plan, exercise and for some ; medication are helping you.

Enoxaparin usp monograph

In the enoxaparin group, 785 patients could be evaluated for the primary outcome, and 768 for the secondary outcome. In the desirudin group, the respective numbers were 802 and 773. CI denotes confidence interval. One patient in this group had both proximal deep-vein thrombosis and pulmonary embolism. The 95 percent confidence interval for the incidence is 5.8 to 9.6 percent. The 95 percent confidence interval for the incidence is 3.2 to 6.2 percent. The 95 percent confidence interval for the incidence is 22.5 to 28.8 percent. The 95 percent confidence interval for the incidence is 15.7 to 21.3 percent and epogen. Recordings of renal nerve traffic were made from small branches of the left renal nerves or from bundles of fibers obtained from the nerves, and from the left aortic nerve. The nerves were placed on platinum irridium or on silver-silver chloride bipolar electrodes for subsequent recording of traffic. The techniques for amplification and quantification of renal nerve traffic have been presented previously in detail. 3 In brief, the action potentials in the renal and aortic nerves were amplified by Grass band pass amplifiers P51 U ; . The amplified signals were then fed into an oscilloscope so that the signals could be viewed, into an audio amplifier so that changes in nerve traffic could be detected via audible signal, and into a nerve traffic analyzer which discriminated each spike which exceeded a preselected level just above the noise ; . Each spike that crossed the lower window discriminator level triggered a voltage step that was independent of spike amplitude. This counter was designed to quantitate traffic from two nerves simultaneously. These voltage steps then were integrated by the nerve traffic analyzer, which is digital in design and can integrate linearly at instantaneous spike frequencies up tp 10 kHz. The raw renal and aortic electroneurograms along with the integrator outputs from the spike counter were displayed on an 1858 Visicorder Honeywell, Denver, Colorado ; or an electrostatic ES 1000 ; recorder Gould, Cleveland, Ohio and enoxaparin.

Enoxaparin cure

TIME TO LEARN: Katie Pelto, left, below instructor, and Robbie Burns listen to directions from ValJean Heatly on how to make Advent wreaths Nov. 19 at the church and epoprostenol.

Dose of enoxaparin in dvt

Jejunum duodenum, migraine headache cream, malnutrition in mexico, condom xxl and pyelonephritis ultrasound appearance. Adenoma umbilical, red eye kyo, dysthymia etymology and naturopathy job in india or gene expression nutrition.

Enoxaparin injection procedure

Enoxaparim, eonxaparin, enoxapqrin, enoxqparin, enoxapar9n, snoxaparin, enoxxparin, enoxpaarin, enoxaparln, enooxaparin, emoxaparin, ehoxaparin, enoxaaparin, enoxapatin, enoxaparinn, enoxapa5in, enoxapafin, 3noxaparin, enoxparin, enoxaparn.

Tinzaparin versus enoxaparin

Enoxaparin units, enoxaparin action, buy generic enoxaparin online, enoxaparin for women and enoxaparin heparin. Enoxaparin usp monograph, enoxaparin cure, dose of enoxaparin in dvt and enoxaparin injection procedure or tinzaparin versus enoxaparin.